Actavis sells Foshan Pharma stake

Share this article:

Actavis's planned China departure is gaining speed. The company announced Friday that it is selling its interest in Foshan Pharmaceuticals to Zhejiang Chiral Medicine Chemicals Co., Ltd.

The company said in a statement that its plan is to “further commercial operations in China in collaboration with its preferred business partners,” but the firm has recently been talking about how the country's business climate is not friendly enough.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.